關(guān)鍵詞： Takeda Amylin 肥胖癥研究
2012年12月29日訊 /生物谷BIOON/ -- Takeda公司取消了與Amylin公司關(guān)于肥胖癥研究的合作協(xié)議,。該協(xié)議總價(jià)值達(dá)超過(guò)美元,，并已進(jìn)行三年之久。
在協(xié)議達(dá)成后,，關(guān)于肥胖癥的研究進(jìn)展迅速,，Arena的新藥Belviq和Vivus的新藥Qsymia都先后獲得批準(zhǔn)。同時(shí)，Amylin公司被Bristol-Myers Squibb公司收購(gòu),，而BMY公司在該領(lǐng)域的研究更加領(lǐng)先,。這都預(yù)示著肥胖癥領(lǐng)域的良好前景。
Takeda公司稱,，今后他們將繼續(xù)加強(qiáng)與其他公司在包括肥胖癥研究在內(nèi)的各領(lǐng)域的合作,。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
Takeda is writing off its three-year-old $1.1 billion pact with Amylin to develop new obesity drugs. The two companies decided to mutually terminate the pact 17 months after they scrapped a midstage study for their pramlintide/metreleptin combo.
"Having greatly benefited from the Amylin team's collective experience and scientific expertise, Takeda will continue to enhance its R&D activities in the area of obesity as well as its other core therapeutic areas to meet the needs of patients," the companies said in a polite joint statement issued on a quiet Christmas Eve.
The biopharma world has changed considerably since Takeda agreed to pay Amylin $75 million upfront to go after the obesity market. Two new drugs, Arena's ($ARNA) Belviq and Vivus's ($VVUS) Qsymia, have since been approved, with Orexigen ($OREX) looking to catch up soon. Amylin was sold to Bristol-Myers Squibb ($BMY), which has other priorities in the pipeline. And there are other experimental drugs in the biotech pipeline whichthat offer considerable promise to dramatically lower weight, a big need in the medical field.
